Formerly About Advanced Micro Devices Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Mick Mørmøny

To: pocotrader who wrote (1306471)	7/3/2021 6:59:52 PM
From: Winfastorlose	1 Recommendation of 1578385

Use of ivermectin in the treatment of Covid-19: A pilot trial Henrique Pott-Junior 1, Mônica Maria Bastos Paoliello 2, Alice de Queiroz Constantino Miguel 3, Anderson Ferreira da Cunha 4, Caio Cesar de Melo Freire 4, Fábio Fernandes Neves 1, Lucimar Retto da Silva de Avó 1, Meliza Goi Roscani 1, Sigrid De Sousa Dos Santos 1, Silvana Gama Florêncio Chachá 1 Affiliations expand PMID: 33723507 PMCID: PMC7942165 DOI: 10.1016/j.toxrep.2021.03.003Free PMC article Abstract Objectives: In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19. Methods: Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov ( NCT04431466). Results: A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests. Conclusions: Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms. Keywords: COVID-19; Ivermectin; SARS-CoV-2. © 2021 The Author(s). Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Figures Graphical abstract Fig. 1 Patient flow diagram. Patients with… Fig. 2 Mean changes in cycle threshold… Fig. 3 Group-wise median cycle threshold reduction…

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next